Standard-of-care treatments for ER+ breast cancer (BC) commonly involve antagonising oestrogen receptor (ER) signalling using aromatase inhibitors or ERα antagonists1,2, ERα degraders (selective oestrogen receptor degraders (SERDs)) such as fulvestrant3 and more recently novel SERD molecules4–6. The gene discussed is CYP19A1; the disease is breast cancer.